834915-92-3Relevant articles and documents
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent
Mulvihill, Mark J.,Kan, Julie L.C.,Cooke, Andrew,Bhagwat, Shripad,Beck, Patricia,Bittner, Mark,Cesario, Cara,Keane, David,Lazarescu, Viorica,Nigro, Anthony,Nillson, Christy,Panicker, Bijoy,Smith, Vanessa,Srebernak, Mary,Sun, Feng-Lei,O'Connor, Matthew,Russo, Suzanne,Fischetti, Gia,Vrkljan, Michael,Winski, Shannon,Castelhano, Arlindo L.,Emerson, David,Gibson, Neil W.
, p. 2729 - 2733 (2006)
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid and analogs were designed and synthesized as highly potent and selective CYP26 inhibitors, serving as retinoic acid metabolic blocking agents (RAMBAs), with demonstrated in vivo efficacy to increase the half-life of exogenous atRA.
NAPHTHYLENE DERIVATIVES AS CYTOCHROME P450 INHIBITORS
-
Page/Page column 156, (2010/02/10)
Compounds of the formula (I); and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G 1,Q1, Z, R1, R2, R3, R4a, R4b, R5a, and R5b are defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and/or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.
